Product category:
Laboratory and scientific professional organisations
News Release from: Cancer Research UK | Subject: Anastrozole (Arimidex)
Edited by the Laboratorytalk Editorial
Team on 29 June 2005
Extension of the anastrozole (Arimidex)
licence
Statement from Cancer Research UK on the extension of the anastrozole (Arimidex) licence says the drug is effective at preventing recurrence of breast cancer
Professor John Toy, Cancer Research UK's medical director, says: "Research is showing that anastrozole is even more effective than tamoxifen in reducing the risk of breast cancer coming back after initial treatment "Until now, the drug has only been available to women who can't take tamoxifen for specific health reasons, such as a high risk of blood clots
This article was originally published on Laboratorytalk on 10 Dec 2003 at 8.00am (UK)
Related stories
New test could prevent more cervical cancer
A new test could be a more effective early warning system for preventing cervical cancer than the traditional smear according to Cancer Research UK scientists
"This extension to the licence means that more women are now eligible for anastrozole.
"However, it's important for women to discuss their treatment options with their doctor and in the meantime they should not stop taking their current treatment.
"To find out whether anastrozole can also prevent breast cancer, Cancer Research UK is currently running a trial, called Ibis-II.
"The trial is open to women across the UK who are post-menopausal and at an increased risk of the disease, for example because they have a family history of breast cancer.".
• Cancer Research UK: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
